Benoist S, Brouquet A, Penna C, Julie C, El Hajjam M, Chagnon S, Mitry E, Rougier P, Nordlinger B. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?
J Clin Oncol. 2006 Aug 20;24(24):3939-45.

Chung KY, Kelsen D. Adjuvant Therapy for Stage II Colorectal Cancer: Who and with What? Curr Treat Options Gastroenterol. 2006 Jun;9(3):272-80.

Oki E, Kakeji Y, Yoshida R, Ikeda K, Nishida K, Koga T, Egashira A, Tokunaga E, Morita M, Baba H, Maehara Y. [A randomized controlled trial to evaluate the effect of adjuvant oral fluoropyrimidine derivative therapy after curative resection for stage II/III rectal cancer-adjuvant chemotherapy trial of S-1 for rectal cancer (ACTS-RC):] Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:138-43. Japanese

Yoshimatsu K, Umehara A, Ishibashi K, Yokomizo H, Yoshida K, Fujimoto T, Watanabe K, Ogawa K. Indication and efficacy of adjuvant chemotherapy with oral fluoropyrimidines for dukes' B colorectal cancer. Anticancer Res. 2006 Jul-Aug;26(4B):3089-93.

Capirci C, Rubello D, Chierichetti F, Crepaldi G, Fanti S, Mandoliti G, Salviato S, Boni G, Rampin L, Polico C, Mariani G.  Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. AJR Am J Roentgenol. 2006 Aug;187(2):W202-8.

Knutsen A, Adell G, Sun XF. Inflammatory infiltration, fibrosis, necrosis and mucinous content in relation to clinicopathological and molecular factors in rectal cancers with or without preoperative radiotherapy. Oncol Rep. 2006 Aug;16(2):321-7.

Ward SE, Kaltenthaler E, Cowan J, Marples M, Orr B, Seymour MT. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
Br J Cancer. 2006 Jul 3;95(1):27-34.

Pelz JO, Doerfer J, Dimmler A, Hohenberger W, Meyer T. Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations. BMC Cancer. 2006 Jun 22;6:162.

Sobrero A. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal. Lancet Oncol. 2006 Jun;7(6):515-6.

Roels S, Duthoy W, Haustermans K, Penninckx F, Vandecaveye V,  Boterberg T, De Neve W. Definition and delineation of the clinical target volume for rectal cancer.  Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1129-42.

Crozier JE, McKee RF, McArdle CS, Angerson WJ, Anderson JH, Horgan PG, McMillan DC. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. Br J Cancer. 2006 Jun 19;94(12):1833-6.

Vulto AJ, Lemmens VE, Louwman MW, Janssen-Heijnen ML, Poortmans PH, Lybeert ML, Coebergh JW. The influence of age and comorbidity on receiving radiotherapy as part of primary treatment for cancer in South Netherlands, 1995 to 2002.
Cancer. 2006 Jun 15;106(12):2734-42.

Burton S, Brown G, Daniels I, Norman A, Swift I, Abulafi M, Wotherspoon A, Tait D. MRI identified prognostic features of tumors in distal sigmoid, rectosigmoid, and upper rectum: treatment with radiotherapy and chemotherapy.
Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):445-51.

Goto A, Yamada Y, Yasui H, Kato K, Hamaguchi T, Muro K, Shimada Y, Shirao K. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.
Ann Oncol. 2006 Jun;17(6):968-73.

Bakx R, Emous M, Legemate DA, Zoetmulder FA, van Tienhoven G, Bemelman WA, van Lanschot JJ. Harm and benefits of short-term pre-operative radiotherapy in patients with resectable rectal carcinomas. Eur J Surg Oncol. 2006 Jun;32(5):520-6.